test

Leadership

Miranda Toledano

Board Member and Chief Executive Officer

Miranda Toledano has served as a member of our Board of Directors since 2018, as prior Chair of the Audit Committee and Member of the Scientific Advisory Committee. Ms. Toledano has served as Entera’s Chief Executive Officer since July 2022. Ms. Toledano has over 25 years of C-level leadership, principal investment and Wall Street/capital market experience in the biotech sector. Previously, Miranda served as Chief Operating Officer, Chief Financial Officer, and Board Member of TRIGR Therapeutics, a stealth oncology focused, clinical stage bispecific antibody company, from August 2018 until its acquisition by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development of lead asset TR009 (now CTX-009, tovecimig) and led strategic execution, including a $117 million China License Transaction and TRIGR’s 2021 acquisition by Compass. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX) from 2004 to 2010. Ms. Toledano is also a member of the board of directors of Journey Medical (Nasdaq: DERM). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.

Felicia Cosman

MD, SAB Chair

Dr. Cosman is Professor of Medicine at Columbia University and a clinical scientist renowned for her work on anabolic therapies and treatment sequencing in osteoporosis. Co‑Editor‑in‑Chief of Osteoporosis International since 2016, she has authored more than 190 peer‑reviewed papers and 50 book chapters, led pioneering teriparatide studies (including combination and sequential regimens), and served as principal investigator for trials of abaloparatide and romosozumab. Her contributions earned the ACE Distinction in Endocrinology (2019) and the ASBMR Bartter Award (2020). She holds a BA from Cornell, an MD from Stony Brook, and completed residency and fellowship at Columbia.

Gregory Burshtein

PhD, Chief of Research and Development

Dr. Burshtein has led research and development at the Company since he joined Entera in September 2012, as Director of Pharmaceutical R&D, and since May 2024, as our Chief of Research and Development. Dr. Burshtein is a leader in the field of oral delivery of peptides, has published in peer-reviewed journals, and holds 25 issued patents and has 113 pending patent applications related to development, formulation, and delivery of oral large molecules. Dr. Burshtein holds over 20 years of experience in the field of drug delivery, pharmacology and biopharmaceutics, with a primary focus on the challenging area of oral delivery of therapeutic peptides. Dr. Burshtein obtained his PhD in Pharmaceutical Sciences, MSc in Clinical Pharmacy, and B. Pharm degree from the Institute for Drug Research, Faculty of Medicine of the Hebrew University of Jerusalem.

Hillel Galitzer

PhD, Chief Operating Officer

Dr. Galitzer has served as our Chief Operating Officer since February 2014, prior to which he served as a Director of Scientific Development from July 2010. Prior to joining Entera, Dr. Galitzer was an analyst and the chief operating officer for Hadasit Bio Holdings Ltd., a publicly traded company on the Tel Aviv Stock Exchange (TASE: HDST) and OTC markets. He is the co-founder and former chief operating officer of Optivasive Inc. Dr. Galitzer received his Ph.D. from the Hebrew University Medical School in Jerusalem, where he was mentored by two world renowned researchers in the areas of parathyroid hormone and calcium regulation, his M.B.A. from Bar Ilan University in Israel and his B.Med.Sc. from the Hebrew University Medical School in Jerusalem.

Rachel B. Wagman

MD, FACE, FACP, Chief Clinical Advisor

Dr. Wagman has served as Entera’s Chief Clinical Advisor since 2024. Dr. Wagman brings over 20 years of career success across the biopharmaceutical industry with a focus on metabolic bone disease and women’s health. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle management. Dr. Wagman’s clinical leadership experiences include progressive roles at Eli Lilly, Amgen, and Myovant Sciences, where as Senior Vice President Clinical Development, she integrated Myovant’s development portfolio into the newly-established Sumitomo Pharma America. She completed her BA at the University of Pennsylvania, MD at Jefferson Medical College, Internal Medicine residency at Thomas Jefferson University Hospital, and postdoctoral fellowship in Endocrinology, Gerontology, and Metabolism at Stanford University School of Medicine. She is a Fellow of both the American College of Endocrinology and the American College of Physicians and holds dual board certifications in Internal Medicine and Endocrinology, Diabetes, and Metabolism.

Dana-Garbeli Yaacov

CPA, Chief Financial Officer

Dana Yaacov-Garbeli has served as our Chief Financial Officer since June 2019. Ms. Yaacov-Garbeli has over 17 years of finance and accounting experience. She previously served as Senior Manager at PwC Israel overseeing audits of public and private companies. She has significant experience in financial planning, operations management, external and internal audit for public multinational companies under US GAAP, IFRS and PCAOB standards. Ms. Yaacov-Garbeli holds a B.A in accounting and business management and an MBA in financial management from The College of Management and Academic studies. Ms. Yaacov-Garbeli is a Certified Public Accountant in Israel.

Cherin Smith

PMP, EVP, Head of Clinical Operations

Cherin is an accomplished leader with over 20 years of experience in Global Clinical Operations Leadership, Project Management, and Vendor Management. With more than a decade of strategic experience in Women’s Health, Cherin has a broad background in various therapeutic areas, including osteoporosis, metabolic, rare diseases, cardiovascular, and CNS disorders. A proven track record in managing and fostering successful CRO and alliance partnerships, serving as a strategic escalation point within cross-functional matrix organizations. Cherin led the successful execution of 11 Phase 3 trials with BMD endpoints, including registrational Phase 3 programs for Orilissa®, Myfembree®, and Veozah®, and has contributed to NDA submissions. Cherin holds a Bachelor of Science, Psychobiology degree from the University of California, Los Angeles (UCLA) and is a certified Project Management Professional (PMP).

Michal Kushnir

Director of Program Management

Michal Kushnir joined Entera in 2024 and is an experienced program manager with 20 years of expertise across biotechnology, pharmaceuticals, and medical devices. She has a proven track record of delivering complex projects from inception to clinical implementation. Ms. Kushnir has successfully led high-impact projects and held senior leadership roles within both biotech and global pharmaceutical companies, collaborating with international teams and stakeholders to drive success. Throughout her career, Ms. Kushnir has excelled at developing strategic plans, building key partnerships, driving cross-functional collaboration, and optimizing project execution to consistently deliver exceptional results. Ms. Kushnir holds an MSc. in Biochemistry from Tel Aviv University (magna cum laude) and a B.Pharm from the Hebrew University of Jerusalem (summa cum laude).

Osnat Bar-Peled

PhD, Executive Director of IP

Dr. Bar-Peled joined Entera in August 2025, as Executive Director of Intellectual Property (IP), bringing over 25 years of expertise in the pharmaceutical industry, with a proven track record across a broad spectrum of patent-related matters. Dr. Bar-Peled extensive experience includes leading complex IP strategies in Freedom-to-Operate assessments, patent validity, Loss-of-Exclusivity analysis, and patent drafting and prosecution. Before joining Entera, Dr. Bar-Peled served as IP  Director at Taro Pharmaceutical Industries – wholly owned by Sun Pharma, one of the largest generic companies in India. Her leadership in IP management at Taro significantly advanced the company’s strategic IP portfolio and its global competitiveness. Dr. Bar-Peled obtained her MSc. and PhD from Weizmann Institute of Science in Molecular Genetics, and completed a Postdoctoral Fellowship at Johns Hopkins University, specializing in Degenerative Neuromuscular Disorders.

Anke Hoppe

VP of Clinical Operations

Anke Hoppe brings over 35 years of global clinical operations experience across leading organizations including Vertex, Sanofi, GSK, and ICON. She has successfully led complex, multinational Phase I–III trials across a wide range of therapeutic areas in biotech, pharma, and CROs. Anke is recognized for her operational excellence, for building high-performing teams and navigating regulatory and logistical challenges in fast-paced environments. Her commitment to quality, timelines, and patient safety has made her a highly trusted leader in clinical development.

Constantin Itin

RPh, PhD, Head of Biopharmaceutics and Bioanalytics

Dr. Itin, RPh, PhD, leads pre-clinical and bioanalytical activities at Entera within the R&D team since joining the Company in 2019. Dr. Itin has over 15 years of experience in the fields of biopharmaceutics, pharmacokinetics and drug delivery. Dr. Itin is author of multiple publications in peer-reviewed journals and patents. Dr. Itin obtained his Ph.D. in Pharmaceutical Sciences and BSc. Pharm degree from the Institute for Drug Research, Faculty of Medicine, at the Hebrew University of Jerusalem, doing his research at the lab of Prof. Amnon Hoffman, a world expert in the field of oral drug delivery.

Scientific Advisory Board

Felicia Cosman

MD, SAB Chair

Dr. Cosman is Professor of Medicine at Columbia University and a clinical scientist renowned for her work on anabolic therapies and treatment sequencing in osteoporosis. Co‑Editor‑in‑Chief of Osteoporosis International since 2016, she has authored more than 190 peer‑reviewed papers and 50 book chapters, led pioneering teriparatide studies (including combination and sequential regimens), and served as principal investigator for trials of abaloparatide and romosozumab. Her contributions earned the ACE Distinction in Endocrinology (2019) and the ASBMR Bartter Award (2020). She holds a BA from Cornell, an MD from Stony Brook, and completed residency and fellowship at Columbia.

Steven R. Goldstein

MD

A Professor of Obstetrics & Gynecology at NYU Grossman School of Medicine, Dr. Goldstein is immediate past President of the International Menopause Society and former President of NAMS. He has written seven women’s‑health books, over 140 research articles, and the IMS white paper on bone health, and has delivered 400+ invited lectures worldwide. Honors include the 2023 William J. Fry Memorial Lecture (AIUM) and Ian Donald Gold Medal (ISUOG) and the 2016 NAMS Clarkson Award, reflecting his leadership in menopause, ultrasound, and mid‑life bone care.

John P. Bilezikian

MD, PhD

The Dorothy L. and Daniel H. Silberberg Professor of Medicine at Columbia University, Dr. Bilezikian is Vice‑Chair for International Education & Research and Chief, Emeritus, of Endocrinology. A past President of ASBMR and ISCD, he has edited flagship journals (JCEM, JBMR) and seminal textbooks, co‑chaired every International Parathyroid Workshop since 2002, and published over 935 papers on parathyroid disorders, vitamin D, and osteoporosis. His accolades span the Endocrine Society Distinguished Physician Award, ASBMR’s three highest honors, and Columbia’s 2019 Gold Medal for Research

Maria Luisa Brandi

MD, PhD

Professor Emerita of Endocrinology at the University of Florence, Prof. Brandi is a globally cited expert in metabolic bone diseases with 930+ publications. She directs the Italian foundations F.I.R.M.O. and O.F.F. Italia, sits on the IOF Board, chairs the IOF Academy on Skeletal Rare Diseases and Capture the Fracture®, and serves on ESCEO’s Board. Her clinical and policy leadership—from Italy’s Ministry of Health to EU rare‑bone networks—has shaped international guidelines, earning her numerous awards and a top‑ten citation ranking in osteoporosis research

Bente Langdahl

MD, PhD

Professor Emerita of Endocrinology at the University of Florence, Prof. Brandi is a globally cited expert in metabolic bone diseases with 930+ publications. She directs the Italian foundations F.I.R.M.O. and O.F.F. Italia, sits on the IOF Board, chairs the IOF Academy on Skeletal Rare Diseases and Capture the Fracture®, and serves on ESCEO’s Board. Her clinical and policy leadership—from Italy’s Ministry of Health to EU rare‑bone networks—has shaped international guidelines, earning her numerous awards and a top‑ten citation ranking in osteoporosis research.

Bruce Mitlak

MD

Former Chief Medical Officer of Radius Health and Distinguished Medical Fellow at Eli Lilly, Dr. Mitlak spent two decades advancing musculoskeletal and women’s‑health therapeutics, notably for osteoporosis. Trained in Internal Medicine and Endocrinology at Harvard Medical School, he has authored 100+ publications—including in NEJM, JAMA, and The Lancet—that underpin several approved bone‑health treatments.

Serge Ferrari

MD, PhD

Professor of medicine, Head of the Clinical Service and Research Laboratory of Bone Diseases,  Vice-Dean for translational research and innovation at the Geneva Faculty of Medicine and University Hospital, Switzerland.

Rogely Boyce

DVM, PhD, DACVP

Dr. Boyce is a well-recognized independent expert with a broad expertise in the field of bone toxicologic pathology. She is a DVM PhD and is a diplomate of the American College of Veterinary Pathology -DACVP specializing in metabolic bone diseases, arthritis, and orthopedics. She has over 35 years of experience in this field and has held several positions in pharmaceutical companies and CROs and is therefore familiar with the drug development process and interaction with regulatory authorities. Dr. Boyce is a member of the International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) group for skeletal tissues, co-author of several book chapters and over 70 publications on bone histopathology or other scientific topics in peer reviewed journals. She also led several meeting sessions on safety considerations of bone therapeutics. For instance, she was the nonclinical expert involved in the meetings in etidronate, denosumab and romosozumab. She participated in FDA committee meetings for etidronate, calcitonin and romosozumab and assisted with preparations for the FDA Advisory committee meeting for denosumab. In addition, she contributed to several nonclinical safety sections in IND, NDA and BLA filings. Dr. Boyce currently runs her own independent consultancy company Beechy Ridge ToxPath LLC based in North Carolina (USA).

© 2025 EnteraBio Ltd.
Privacy Policy
A-2-Z - Digital Accessibility and Marketing